Skip to search formSkip to main contentSkip to account menu

MOR-14

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
N-methyl-1-deoxynojirimycin (MOR-14), an α-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction
2001
2001
Role of protein kinase C in the reduction of infarct size by N‐methyl‐1‐deoxynojirimycin, an α‐1,6‐glucosidase inhibitor
Preischaemic treatment with N‐methyl‐1‐deoxynojirimycin (MOR‐14), an α‐1,6‐glucosidase inhibitor, attenuates glycogenolysis and… 
2000
2000
N-Methyl-1-deoxynojirimycin (MOR-14), an α-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction
Abstract We examined whether pharmacological inhibition of glycogenolysis by N-methyl-1-deoxynojirimycin (MOR-14), a new compound… 
1998
1998
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts.
BACKGROUND N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, reduces the glycogenolytic rate by inhibiting… 
1998
1998
N-Methyl-1-Deoxynojirimycin (MOR-14), an α-Glucosidase Inhibitor, Markedly Reduced Infarct Size in Rabbit Hearts
Background—N-methyl-1-deoxynojirimycin (MOR-14), an α-glucosidase inhibitor, reduces the glycogenolytic rate by inhibiting the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)